A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease

Inclusion Criteria

• •Have clinical features of HD and a CAG polyglutamate repeat expansion ≥ 36
• •Have cognitive impairment as noted by the following:
• •1. A Screening MMSE AND a baseline (pre-dose) MMSE score between 10 and 26 (inclusive); and
• •2. A subjective assessment of cognitive impairment with decline from pre-HD levels by the Investigator after interviewing the subject and caregiver;
• •Are willing and able to give informed consent
• •Aged 30 years or older
• •Have a caregiver who assists/spends time with the subject at least five days per week for at least three hours per day and has intimate knowledge of the subject's cognitive, functional, and emotional states, and of the subject's personal care.